January 2024 Surveillance Definitions
17 - 13
Enterococcus spp.) identified from ≥2 matching blood collections drawn on separate occasions
with no more than 1 calendar day between specimens by a culture or non-culture based
microbiologic testing method which is performed for purposes of clinical diagnosis or
treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
b. Coxiella burnetii identified by anti-phase I IgG antibody titer >1:800 or identified from blood by
a culture or non-culture based microbiologic testing method which is performed for purposes of
clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
5. At least three of the following (Note: Meaning one element from i, ii, iii, or iv and only one condition
within each element can be used.)
i. prior endocarditis, prosthetic valve, uncorrected congenital heart disease, history of rheumatic
heart disease, hypertrophic obstructive cardiomyopathy, or known IV drug use.
§
ii. fever (>38.0°C)
iii. vascular phenomena: major arterial emboli (specifically, embolic stroke, renal infarct, splenic
infarct or abscess, digital ischemic/gangrene from embolic source), septic pulmonary infarcts,
mycotic aneurysm (documented by imaging, seen in surgery, or described in gross pathological
specimen), intracranial hemorrhage, conjunctival hemorrhages, or Janeway’s lesions documented.
iv. immunologic phenomena: glomuleronephritis (documented in chart, or white cell or red blood cell
casts on urinalysis), Osler’s nodes, Roth’s spots, or positive rheumatoid factor.
a. typical infectious endocarditis organism(s) (specifically, Viridans group streptococci,
Streptococcus bovis, Haemophilus spp., Actinobacillus actinomycetemcomitans,
Cardiobacterium hominis, Eikenella corrodens, Kingella spp., Staphylococcus aureus,
Enterococcus spp.) identified from ≥2 matching blood collections drawn on separate occasions
with no more than 1 calendar day between specimens by a culture or non-culture based
microbiologic testing method which is performed for purposes of clinical diagnosis or
treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
b. Coxiella burnetii identified by anti-phase I IgG antibody titer >1:800 or identified from blood by
a culture or non-culture based microbiologic testing method which is performed for purposes of
clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
6. At least one of the following*‡:
ii. intracardiac abscess seen on echocardiogram
And at least one condition from three of the following elements: a. prior endocarditis, prosthetic valve, uncorrected congenital heart disease, history of rheumatic
heart disease, hypertrophic obstructive cardiomyopathy, or known IV drug use.
§
b. fever (>38.0°C)
c. vascular phenomena: major arterial emboli (specifically, embolic stroke, renal infarct, splenic
infarct or abscess, digital ischemic/gangrene from embolic source), septic pulmonary infarcts,
mycotic aneurysm (documented by imaging, seen in surgery, or described in gross pathological
specimen), intracranial hemorrhage, conjunctival hemorrhages, or Janeway’s lesions
documented.
d. immunologic phenomena: glomuleronephritis (documented in chart, or white cell or red blood
cell casts on urinalysis), Osler’s nodes, Roth’s spots, or positive rheumatoid factor.
e. identification of organism(s) from the blood by at least one of the following methods: